The role of cefotaxime in the treatment of surgical infections

Abstract

This study examines the role of cefotaxime in the treatment of both Gram-negative and Gram-positive surgical infections. A dose of 2 g of cefotaxime will sustain peripheral compartment concentrations of 2.6, 3.9, 1.6, and 0.7 micrograms/ml for 6, 8, 10 and 12 h, respectively. Therefore, the proportion of pathogens with a minimal inhibitory concentration (MIC) below the peripheral compartment cefotaxime concentrations was assessed as a measure of therapeutic potential. It was observed that bacterial elimination in infections correlates well with such pharmacodynamic predictions. Therefore, treatment recommendations for surgical infections are based on the following pharmacodynamics. The times above the MIC in the tissue compartment for various pathogens (1988-1994) known to cause surgical infections were: Escherichia coli, 12 h; all pyogenic streptococci, 12 h; pneumococci, 12 h; Haemophilus spp., 12 h; Proteus mirabilis, 12 h; Klebsiella spp., 10.9 h; viridans streptococci, 10.6 h; oxacillin-susceptible, coagulase-negative staphylococci, 9.7 h; Providencia spp., 9.2 h; Clostridium perfringens, 8.6 h; Peptostreptococcus spp., 8 h; oxacillin-susceptible Staphylococcus aureus, 7.3 h; and all S. aureus, 6.8 h. From the examination of pharmacodynamic parameters, cefotaxime appears to be a viable choice for the therapy of surgical infections other than the Gram-negative anaerobes. For those infections, metronidazole with cefotaxime would be preferred.